GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

1. Partnership Details: GSK has partnered with Flagship Pioneering to develop up to 10 novel medicines and vaccines, focusing initially on respiratory and immunology indications.
2. Funding: The partnership will jointly fund up to $150 million upfront for an exploration phase to identify promising scientific concepts.
3. Milestone Payments: Flagship and its companies could receive up to $720 million in milestone payments for each program acquired by GSK, plus royalties from sales of commercialized products.
4. Flagship's Ecosystem: Flagship has founded over 40 bioplatform companies, including Moderna, and plans to create and develop about 25 startups with its new $2.6 billion fund.
5. GSK's Expertise: GSK brings its disease area expertise and development capability to the partnership, aiming to accelerate its pipeline and discover practice-changing medicines and vaccines.